Medical Access in France

Psilocybin and psilocin are listed in the French narcotics framework, and no routine medical prescribing route exists. Patient access is currently limited to authorised clinical research, including France-based studies at CHU Nimes and the Paris COMP006 and PSILOTRAZ pipeline. [1]Legifrance narcotics list order of 22 February 1990 [2]Sante.fr psilocybin treatment-resistant depression pilot [3]CTIS psilocybin psychogenic non-epileptic seizures pilot [4]GHU Paris COMP006 update [5]CTIS PSILOTRAZ trial record

MDMA is listed in the French narcotics framework. No French market authorisation, reimbursement route or routine therapeutic pathway for MDMA-assisted therapy was identified in the official sources reviewed. [1]Legifrance narcotics list order of 22 February 1990

Esketamine nasal spray is authorised as Spravato, but practical access is hospital-centred. The public medicines database lists the marketed nasal presentation as prescription-only, hospital use, approved for collectivity, and non-reimbursable in community pharmacy. [1]French public medicines database Spravato entry

HAS supports restricted use in treatment-resistant depression but was unfavourable for the depressive-emergency extension involving acute suicidal ideation. France's 2026 anti-suicidal access change therefore comes through racemic ketamine CPC, not a broad retail reimbursed Spravato route. [2]HAS Spravato transparency committee opinion 17 July 2024 [3]HAS Spravato transparency committee opinion 22 September 2021 [4]ANSM ketamine CPC decision

Ketamine is an authorised hospital medicine for anaesthesia and selected emergency, pain and palliative indications. The French medicines database lists Ketamine Renaudin as prescription-only, hospital-use, and a controlled medicine with restricted prescription and administration conditions. [1]French public medicines database Ketamine Renaudin entry

In March 2026, ANSM established a CPC for IV racemic ketamine in severe suicidal ideation in adults. This is a hospital-based compassionate prescribing framework with pharmacovigilance obligations, not a broad outpatient psychiatric ketamine market. ANSM has also warned about risks from prolonged or repeated ketamine use. [2]ANSM ketamine CPC decision [3]ANSM ketamine CPC protocol [4]ANSM reminder on proper ketamine use

DMT is listed in the French narcotics framework. No French market authorisation, reimbursement route or routine medical access pathway for DMT-assisted therapy was identified in the sources reviewed. [1]Legifrance narcotics list order of 22 February 1990

No French market authorisation, reimbursement route or routine medical access pathway for 5-MeO-DMT was identified in the reviewed public sources. The report avoids a definitive compound-level scheduling claim for 5-MeO-DMT pending manual verification in current primary law. [1]Legifrance narcotics list order of 22 February 1990

No French market authorisation, reimbursement route or routine medical access pathway for ibogaine was identified in the reviewed public sources. Any future legal-status table should verify ibogaine directly against the current French narcotics list. [1]Legifrance narcotics list order of 22 February 1990

France added several ayahuasca-source plants and related alkaloids to the narcotics list in 2005, including Banisteriopsis caapi, Psychotria viridis, Peganum harmala and harmala alkaloids. No ceremonial or medical access carve-out was identified in the official framework reviewed. [1]Legifrance order of 20 April 2005 on ayahuasca-related plants and alkaloids

Mescaline is listed in the French narcotics framework. No French market authorisation, reimbursement route or routine medical access pathway for mescaline-assisted therapy was identified in the sources reviewed. [1]Legifrance narcotics list order of 22 February 1990

No French authorised or reimbursed medical pathway for the broad 2C-X category was identified. Because the category covers multiple compounds, any legal-status grid should verify specific molecules rather than relying on a generic class label. [1]Legifrance narcotics list order of 22 February 1990